Completed × Pancreatic Neoplasms × Erlotinib Hydrochloride × Clear all Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Phase 1 Completed
30 enrolled
Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
Phase 1 Completed
14 enrolled
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Phase 1 Completed
95 enrolled
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
134 enrolled 12 charts
GEM
Phase 2 Completed
120 enrolled
Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
Phase 1 Completed
24 enrolled
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Completed
20 enrolled 11 charts
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Phase 1/2 Completed
81 enrolled 19 charts
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Completed
46 enrolled 13 charts
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Phase 2 Completed
48 enrolled 11 charts
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Phase 1 Completed
14 enrolled
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
Phase 3 Completed
569 enrolled
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Phase 2 Completed
123 enrolled 10 charts
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Completed
338 enrolled 18 charts
Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
Phase 1 Completed
15 enrolled
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
Phase 2 Completed
36 enrolled 10 charts
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
Phase 1 Completed
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Phase 3 Completed
569 enrolled
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Phase 2 Completed
30 enrolled 7 charts
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Phase 2 Completed
37 enrolled
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Phase 1 Completed
28 enrolled
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Phase 2 Completed
32 enrolled 12 charts
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Completed
104 enrolled 10 charts
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Phase 3 Completed
80 enrolled 10 charts
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Phase 1 Completed
27 enrolled 6 charts
TARGET
Phase 1/2 Completed
44 enrolled
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Phase 1 Completed
17 enrolled
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
Phase 2 Completed
45 enrolled 8 charts
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Phase 2 Completed
207 enrolled 12 charts
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
Phase 3 Completed
820 enrolled
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Phase 2 Completed
153 enrolled 16 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Phase 1 Completed
32 enrolled 13 charts
TART
Phase 1 Completed
12 enrolled 6 charts
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Phase 2 Completed
467 enrolled 21 charts
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Phase 2 Completed
143 enrolled 9 charts
GEMOX-T
Phase 2 Completed
33 enrolled
Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
Phase 1 Completed
8 enrolled
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
Phase 1 Completed
28 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
Phase 2 Completed
22 enrolled
A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Phase 1 Completed
20 enrolled
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
Phase 2 Completed
109 enrolled 9 charts
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
Phase 1 Completed
23 enrolled
Tarceva and Capecitabine for Pancreatic Cancer
Phase 2 Completed
32 enrolled